CLEAR III Intraventricular Thrombolysis Trial
Resolving IVH to improve outcomes
Home
Site Start-up
Study Documents
Monthly Teleconferences
About Us
Contact Us
Participating Sites
Links

Welcome to the CLEAR III Home Page

 
CLEAR III is a Phase III randomized clinical trial (RCT) using recombinant tissue plasminogen activator (rtPA, Cathflo® Activase,® Genentech, Inc., San Francisco, CA) to treat subjects with intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH), and hydrocephalus.


The primary aim of the study is to determine whether rapid removal of IVH clot with low-dose rtPA more likely improves modified Rankin Scores at 6 months (Rankin 0-3) compared to subjects treated with best medical care alone.

 

Upcoming Investigators' Meeting 

 

Investigators who will be attending the upcoming Int'l Stroke Conference (Feb, San Antonio) are incouraged to plan to join for a meeting .  Click here for details. 

 

 

 

  Monthly Teleconferences             

 

The CLEAR III study group will be holding monthly teleconferences on the third Thursday of each month at 8am and 2pm EST.  Click here to register. 

     

  Pharmacist Training Sessions      


Updated dates and times for the CLEAR III Pharmacist Training sessions have been posted.  Click here to register for an upcoming session.  

 

The CLEAR III Trial is led by Study Chairman and co-Principal Investigator Dr. Daniel Hanley of

Johns Hopkins Medicine.  The study Surgical Center the University of Chicago Hospitals is led

by co-Principal Investigator Dr. Issam Awad.